跳至主要内容
临床试验/NCT01053832
NCT01053832已完成不适用

Ventricular Pace Suppression Study With the EVIA/ENTOVIS DR-T/DR Pacemaker

Biotronik SE & Co. KG2 个研究点 分布在 1 个国家目标入组 84 人开始时间: 2010年1月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
84
试验地点
2
主要终点
Reduction of right ventricular pacing with the help of the VpS algorithm in the EVIA/ ENTOVIS pacemakers.

研究概览

简要总结

Investigation of the efficacy and safety of the Ventricular Pace Suppression (VpS) algorithm.

详细描述

The aim of this study is to investigate the percentage of reduction of ventricular pacing using the VpS feature of the EVIA/ENTOVIS pacemaker in a controlled clinical investigation.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Supportive Care
盲法
Single (Participant)

入排标准

性别
All
接受健康志愿者
否

入选标准

  • •Paroxysmal AV block and/or Sinus Node Dysfunction
  • •DDD(R)-ADI(R)-Mode (VpS Algorithm) applicability

排除标准

  • •Permanent AV block III°
  • •Permanent Atrial Fibrillation/ Flutter
  • •Require mode other than DDD(R)-ADI(R) or DDD(R)
  • •Have a life expectancy of less than six months
  • •Expected to receive heart surgery within six months
  • •Enrolled in another cardiac investigation

研究组 & 干预措施

Ventricular Pace Suppression- ON

Other

干预措施: VpS algorithm in EVIA and ENTOVIS pacemakers (Device)

Ventricular Pace Suppression- OFF

Other

干预措施: VpS algorithm in EVIA and ENTOVIS pacemakers (Device)

结局指标

主要结局

Reduction of right ventricular pacing with the help of the VpS algorithm in the EVIA/ ENTOVIS pacemakers.

时间窗: 6-8 months

次要结局

  • A Complication free rate >95%, with respect to the VpS feature of the implanted pacemaker.(6-8 months)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验